DANVILLE, CA – Eyedetec Medical, Inc., a medical device company focused on developing innovative, next-generation treatments for dry eye disease, announced the appointment of Tom Dunlap to its Board of Directors.
“We are pleased to have Tom Dunlap join our Board of Directors. Tom brings a wealth of eyecare industry leadership experience and will fit well with our existing team,” said Eyedetec Medical’s President & CEO, Barry J. Linder, MD, MS. Tom has extensive experience in the ophthalmic and optometric industries in both large, well-established companies and innovative start-ups.
Tom Dunlap is a senior executive with relevant expertise in business strategy and commercialization in many eyecare medical device businesses. His proven track record includes experience in entrepreneurial ventures and multinational companies. Currently, Tom is serving as the Chief Executive Officer of TECLens, Inc. He has held executive management positions at Mynosys Cellular Devices (Centricity Vision), HOYA Surgical Optics, Allergan Medical Optics (J&J Vision), Bausch + Lomb, American Hospital Supply Corporation, Surgilase, and Coherent. He brings experience as an Independent Board member, Non-Executive Director, and Chairman of the Board with private Ophthalmic medical device companies. Tom holds an MBA, with honors from the University of Southern California in Los Angeles, California, and a BA, with honors from Ashland University in Ashland, Ohio.
Mr. Dunlap commented on joining the company’s Board of Directors, “I am honored to be appointed to the Board of Directors and excited about Eyedetec Medical’s future, especially the significant opportunity launching the Eye Lipid Mobilzer™ with Vibration Induced Shear Thinning™ to treat evaporative dry eye disease in the United States (pending FDA clearance). Barry has set the company on strong footing with an incredibly strong team, and a novel device which will expand treatment options by providing advanced treatment in the office and at home that is effective, affordable, and convenient. We are well positioned to continue to deliver for patients and the physicians who serve them, while increasing value for our shareholders.”
About Eyedetec Medical, Inc.
Eyedetec Medical is a privately held medical device company with one commercial product intended to treat mild evaporate dry eye disease, as well as the Eye Lipid Mobilizer™ pending FDA clearance to treat moderate to severe disease. With these products, Eyedetec is addressing the large and growing unmet need for effective dry eye treatment options with both affordable and convenient products. For more information, please visit www.eyedetec.com.
Contacts:
Investor and Medial Inquiries:
Barry J Linder, MD, MS, President & CEO
(m) 650-224-1604
